Vergelijking
Desmopressin vs. Pasireotid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
16679-58-6
396091-73-9
Molecuulmassa
1069.2 g/mol
1047.21 g/mol
Halfwaardetijd
3 h
geen gegevens
Sequentie
Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (Disulfid 1-6)geen gegevens
Werkingsmechanisme
Desmopressin
Desmopressin is a structurally modified analogue of the nine-residue peptide hormone vasopressin. Deamination at the N-terminus (1-deamino) and replacement of L-arginine by D-arginine at position 8 prolong the duration of action and render the compound largely selective for the vasopressin V2 receptor, while the V1-mediated vasoconstrictive effect is strongly reduced. Acting on V2 receptors in the renal collecting ducts, it promotes insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and reducing urine volume (antidiuretic effect). In addition, via V2 receptors on the vascular endothelium, desmopressin stimulates the release of von Willebrand factor and factor VIII from endothelial stores (Weibel-Palade bodies), improving primary haemostasis.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
1
waarvan bij mensen
4
1
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Desmopressin and Pasireotid?
- Desmopressin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Desmopressin: Desmopressin (DDAVP) is a synthetic analogue of the endogenous hormone vasopressin (antidiuretic hormone, ADH). Deamination of the first amino acid and substitution of L-arginine with D-arginine give it selective activity at the V2 receptor with strongly reduced pressor (V1) activity. It has been approved for decades for indications including central diabetes insipidus, primary nocturnal enuresis, and bleeding tendency in von Willebrand disease type 1 and mild haemophilia A. The principal safety concern is hyponatremia or water intoxication. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Desmopressin or Pasireotid?
- The highest available evidence level is "Humane RCT" for Desmopressin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Desmopressin and Pasireotid in Germany and the United States?
- Duitsland: Desmopressin — Op recept, Pasireotid — Op recept. Verenigde Staten: Desmopressin — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.